CXCL5 and hepatocellular carcinoma: Additionally, CXCL5 has been demonstrated to possess the ability to activate the PI3K-AKT signalling pathway in hepatocellular carcinomas [20] and colorectal cancer [25] cells via its receptor CXCR2.